Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $45.602 million which missed the analyst consensus estimate of $46.479 million by 1.89 percent. This is a 2.18 percent decrease over sales of $46.617 million the same period last year.